Full Press Release Details
Last Accessed November 23, 2021. 2. Pan s J, et al. Gut. 2017 Jun;66(6):1049-1059. 3. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Last Accessed November 23, 2021. 4. Sandborn WJ, et al. J Crohns Colitis. 2020 Sep 16;14(9):1202-1213. 5. Data on file. * All trademarks are the property of their respective owners.
There is currently no combination regimen based on FOLFIRINOX - Broad Utility: Potential in preoperative, postoperative and metastatic settings and impact beyond PDAC MK2 Inhibitor Value Proposition 37 The preclinical studies supporting this approach are now accepted in Science Translational Medicine.2 1. Conroy T, et al. N Engl J Med. 2018 Dec 20;379(25):2395-2406. 2.
Murali B, et al. Cancer Res. 2018 Oct 1;78(19):5618-5630. 2. Sparano JA, et al. N Engl J Med. 2008 Apr 17;358(16):1663-71. 3. Polascik TJ, et al. Ther Clin Risk Manag. 2008;4(1):261-268. Bone Metastasis1 Ctrl Zunsemetinib Trabecular Bone Volume1 Zunsemetinib (ATI-450) Zoledronic acid ATI-450 *Bone quality in untreated diseased animals was too low to measure (0.0 on the Y-axis) Copyright 2020 Aclaris Therapeutics, Inc.
These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Cautionary Note Regarding Forward-Looking Statements 2 Copyright 2020 Aclaris Therapeutics, Inc.
Securities and Exchange Commission from time to time. These documents are available under the SEC Filings" page of the Investors section of Aclaris' website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this presentation and are based on information available to Aclaris as of the date of this presentation, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry.
These forward-looking statements include expectations regarding Aclaris' development of its drug candidates, including the timing of its clinical trials and regulatory submissions. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, the uncertainty regarding the COVID-19 pandemic including its impact on the timing of Aclaris' regulatory and research and development activities, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2020 and other filings Aclaris makes with the U.S.